Genetic variation in the progesterone receptor gene and risk of endometrial cancer: A haplotype-based approach

Carcinogenesis

Volumn 31, Issue 8, 2010, Pages 1392-1399

  Lee, Eunjung ^a   Hsu, Chris ^a   Haiman, Christopher A ^a   Razavi, Pedram ^a   Horn Ross, Pamela L ^b   van Den Berg, David ^a   Bernstein, Leslie ^c   Le marchand, Loic ^d   Henderson, Brian E ^a   Setiawan, V Wendy ^a   Ursin, Giske ^a,e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ALLELE; ARTICLE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; ENDOMETRIUM CANCER; ETHNICITY; EUROPEAN AMERICAN; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; PGR GENE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEPTOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; ENDOMETRIAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HAWAII; HISPANIC AMERICANS; HUMANS; LINKAGE (GENETICS); ODDS RATIO; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 77955372079     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq113     Document Type: Article

References (41)

1. Ries, L.A.G. et al. (2008) SEER Cancer Statistics Review, 1975-2005. National Cancer Institute, Bethesda, MD.
2. Key, T.J. et al. (1988) The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br. J. Cancer, 57, 205-212.
3. Olson, S.H. et al. (2007) Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review. Am. J. Epidemiol., 165, 235-245.
4. King, R.J. et al. (1981) Assessment of oestrogen and progestin effects on epithelium and stroma from preand postmenopausal endometria. J. Steroid Biochem., 15, 175-181.
5. Pike, M.C. et al. (2000) Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids, 65, 659-664.
6. Pike, M.C. et al. (1997) Estrogen-progestin replacement therapy and endometrial cancer. J. Natl Cancer Inst., 89, 1110-1116.
7. Rowe, S.M. et al. (1995) Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion. Cancer Res., 55, 2743-2745.
8. Romano, A. et al. (2007) The PROGINS polymorphism of the human progesterone receptor diminishes the response to progesterone. J. Mol. Endocrinol., 38, 331-350.
9. Agoulnik, I.U. et al. (2004) A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J. Clin. Endocrinol. Metab., 89, 6340-6347.
10. Leite, D.B. et al. (2008) Progesterone receptor (PROGINS) polymorphism and the risk of ovarian cancer. Steroids, 73, 676-680.
11. McKenna, N.J. et al. (1995) A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma. Br. J. Cancer, 71, 451-455.
12. Pearce, C.L. et al. (2005) Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis. J. Natl Cancer Inst., 97, 51-59.
13. Romano, A. et al. (2006) Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer. Gynecol. Oncol., 101, 287-295.
14. Tong, D. et al. (2001) Analysis of the human progesterone receptor gene polymorphism progins in Austrian ovarian carcinoma patients. Int. J. Cancer, 95, 394-397.
15. Lancaster, J.M. et al. (2003) No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, casecontrol study in North Carolina. Cancer Epidemiol. Biomarkers Prev., 12, 226-227.
16. Manolitsas, T.P. et al. (1997) No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer. Br. J. Cancer, 75, 1398-1399.
17. Pearce, C.L. et al. (2008) Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. Br. J. Cancer, 98, 282-288.
18. Pijnenborg, J.M. et al. (2005) Aberrations in the progesterone receptor gene and the risk of recurrent endometrial carcinoma. J. Pathol., 205, 597-605.
19. De Vivo, I. et al. (2002) A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc. Natl Acad. Sci. USA, 99, 12263-12268.
20. Junqueira, M.G. (2007) Progesterone receptor (PROGINS) polymorphism and the risk of endometrial cancer development. Int. J. Gynecol. Cancer, 17, 229-232.
21. Mulac-Jericevic, B. et al. (2004) Reproductive tissue selective actions of progesterone receptors. Reproduction, 128, 139-146.
22. Mulac-Jericevic, B. et al. (2000) Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science, 289, 1751-1754.
23. Dossus, L. et al. (2006) No association between progesterone receptor gene +331G/A polymorphism and endometrial cancer. Cancer Epidemiol. Biomarkers Prev., 15, 1415-1416.
24. Rebbeck, T.R. et al. (2006) Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J. Natl Cancer Inst., 98, 1311-1320.
25. Kolonel, L.N. et al. (2000) A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am. J. Epidemiol., 151, 346-357.
26. Setiawan, V.W. et al. (2009) Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiol. Biomarkers Prev., 18, 242-247.
27. Haiman, C.A. et al. (2003) A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Hum. Mol. Genet., 12, 2679-2692.
28. Bernstein, L. et al. (2002) High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control, 13, 625-635.
29. Razavi, P. et al. (2010) Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol. Biomarkers Prev, 19, 475-483.
30. Gabriel, S.B. et al. (2002) The structure of haplotype blocks in the human genome. Science, 296, 2225-2229.
31. Excoffier, L. et al. (1995) Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol. Biol. Evol., 12, 921-927.
32. Stram, D.O. et al. (2003) Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum. Hered., 55, 27-36.
33. Amant, F. et al. (2005) Endometrial cancer. Lancet, 366, 491-505.
34. Barrett, J.C. et al. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263-265.
35. Hale, G.E. et al. (2002) Endometrial cancer: hormonal factors, the perimenopausal "window of risk," and isoflavones. J. Clin. Endocrinol. Metab., 87, 3-15.
36. Kaaks, R. et al. (2002) Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol. Biomarkers Prev., 11, 1531-1543.
37. Key, T.J. et al. (2003) Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J. Natl Cancer Inst., 95, 1218-1226.
38. Risch, H.A. (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J. Natl Cancer Inst., 90, 1774-1786.
39. Storey, D.J. et al. (2008) Endometrioid epithelial ovarian cancer: 20 years of prospectively collected data from a single center. Cancer, 112, 2211-2220.
40. Kline, R.C. et al. (1990) Endometrioid carcinoma of the ovary: retrospective review of 145 cases. Gynecol. Oncol., 39, 337-346.
41. Soliman, P.T. et al. (2004) Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol. Oncol., 94, 456-462.